Celldex Therapeutics
CLDX
171 hedge funds and large institutions have $1.39B invested in Celldex Therapeutics in 2015 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 63 increasing their positions, 47 reducing their positions, and 20 closing their positions.
51% more capital invested
Capital invested by funds: $917M → $1.39B (+$469M)
50% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 20
34% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 47
6% more funds holding
Funds holding: 162 → 171 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less call options, than puts
Call options by funds: $25.4M | Put options by funds: $27.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$38M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$11.8M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$10.6M |
| 4 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$7.27M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$6.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$20.6M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$16.9M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$10.5M |
| 4 |
Millennium Management
New York
|
-$6.61M |
| 5 |
O
OppenheimerFunds
New York
|
-$4M |
CLDX Hedge Fund Activity: Q4 2015 in Review
171 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2015, worth a combined $1.39B — up 51% from $917M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new CLDX positions and 20 closed out — a net gain of 10 holders — while 63 added to existing stakes and 47 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $38M. The largest seller was Redmile Group, exiting entirely with an estimated $20.6M sold.
- 171 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2015, up from 162 in Q3 2015.
- Funds reported $1.39B of Celldex Therapeutics stock for Q4 2015, up 51% quarter-over-quarter.
- 30 funds opened new Celldex Therapeutics positions in Q4 2015 and 20 closed out, a net change of +10 holders.
- The largest Celldex Therapeutics buyer in Q4 2015 was First Trust Advisors, an estimated $38M added.
- The largest Celldex Therapeutics seller in Q4 2015 was Redmile Group, an estimated $20.6M sold.
Based on aggregated 13F filings for Q4 2015.